Silent partner in blood vessel homeostasis? Pervasive role of nitric oxide in vascular disease

Current Hypertension Reviews

Volumn 5, Issue 4, 2009, Pages 273-282

  Deeb, Ruba S ^b   Lamon, Brian D ^a   Hajjar, David P ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NONE

Author keywords

Angiotensin; Cyclooxygenase; Nitric oxide; Nitrotyrosine; Prostaglandins; Vascular disease

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN II; ARGININE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PROSTAGLANDIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TETRAHYDROBIOPTERIN; TYROSINE;

ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; HOMEOSTASIS; HYPERTENSION; LOW DRUG DOSE; NITRATION; NONHUMAN; OXIDATION; OXIDATIVE PHOSPHORYLATION UNCOUPLING; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; THROMBOCYTE AGGREGATION; VASCULAR DISEASE;

EID: 73449103587     PISSN: 15734021     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340209789587726     Document Type: Review

References (125)

1. Gruetter CA, Barry BK, McNamara DB, Gruetter DY, Kadowitz PJ, Ignarro L. Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. J Cyclic Nucleotide Res 1979; 5: 211-24.
2. Mellion BT, Ignarro LJ, Ohlstein EH, Pontecorvo EG, Hyman AL, Kadowitz PJ. Evidence for the inhibitory role of guanosine 3', 5'-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 1981; 57: 946-55.
3. Heitzer T, Brockhoff C, Mayer B, et al. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers - Evidence for a dysfunctional nitric oxide synthase. Circ Res 2000; 86: E36-E41.
4. Drexler H, Zeiher AM, Meinzer K, Just H. Correction of Endothelial Dysfunction in Coronary Microcirculation of Hypercholesterolemic Patients by L-Arginine. Lancet 1991; 338: 1546-50.
5. Panza JA, Quyyumi AA, Brush JE, Jr., Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22-7.
6. Ming XF, Barandier C, Viswambharan H, et al. Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation 2004; 110: 3708-14.
7. Marcus AJ, Safier LB. Thromboregulation: multicellular modulation of platelet reactivity in hemostasis and thrombosis. FASEB J 1993; 7: 516-22.
8. Anderson TJ. Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. Heart Fail Rev 2003; 8: 71-86.
9. Bautista LE. Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. J Hum Hypertens 2003; 17: 223-30.
10. Marcus AJ, Broekman MJ, Drosopoulos JH, et al. Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection. Semin Thromb Hemost 2005; 31: 234-46.
11. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease - From marvel to menace. Circulation 2006; 113: 1708-14.
12. Xie QW, Cho HJ, Calaycay J, et al. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science 1992; 256: 225-8.
13. Busse R, Mulsch A. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS Lett 1990; 275: 87-90.
14. Kilbourn RG, Belloni P. Endothelial cell production of nitrogen oxides in response to interferon gamma in combination with tumor necrosis factor, interleukin-1, or endotoxin. J Natl Cancer Inst 1990; 82: 772-6.
15. Stroes E, Kastelein J, Cosentino F, et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 1997; 99: 41-6.
16. Drexler H, Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol 1999; 31: 51-60.
17. Landmesser U, Dikalov S, Price SR, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003; 111: 1201-9.
18. Negro R. Endothelial effects of antihypertensive treatment: focus on irbesartan. Vasc Health Risk Manag 2008; 4: 89-101.
19. Klatt P, Schmidt K, Lehner D, Glatter O, Bachinger HP, Mayer B. Structural analysis of porcine brain nitric oxide synthase reveals a role for tetrahydrobiopterin and L-arginine in the formation of an SDS-resistant dimer. EMBO J 1995; 14: 3687-95.
20. Klatt P, Schmidt K, Brunner F, Mayer B. Inhibitors of brain nitric oxide synthase. Binding kinetics, metabolism, and enzyme inactivation. J Biol Chem 1994; 269: 1674-80.
21. Liu Q, Gross SS. Binding sites of nitric oxide synthases. Methods Enzymol 1996; 268: 311-24.
22. Haque MM, Panda K, Tejero J, et al. A connecting hinge represses the activity of endothelial nitric oxide synthase. Proc Natl Acad Sci USA 2007; 104: 9254-9.
23. Bec N, Gorren AC, Voelker C, Mayer B, Lange R. Reaction of neuronal nitric-oxide synthase with oxygen at low temperature. Evidence for reductive activation of the oxy-ferrous complex by tetrahydrobiopterin. J Biol Chem 1998; 273: 13502-8.
24. Stuehr D, Pou S, Rosen GM. Oxygen reduction by nitric-oxide synthases. J Biol Chem 2001; 276: 14533-6.
25. Wei CC, Wang ZQ, Tejero J, et al. Catalytic reduction of a tetrahydrobiopterin radical within nitric-oxide synthase. J Biol Chem 2008; 283: 11734-42.
26. Forstermann U, Closs EI, Pollock JS, et al. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994; 23: 1121-31.
27. Martasek P, Liu Q, Liu JW, Roman LJ, Gross SS, Sessa WC, Masters BSS. Characterization of bovine endothelial nitric oxide synthase expressed in E-coli. Biochem Biophys Res Commun 1996; 219: 359-65.
28. Han SH, Quon MJ, Koh KK. Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction. Curr Opin Lipidol 2007; 18: 58-65.
29. Ross R. Atherosclerosis - An inflammatory disease. N Engl J Med 1999; 340: 1929-.
30. Thomas SR, Witting PK, Drummond GR. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 2008; 10: 1713-65.
31. Freeman BA, Young SL, Crapo JD. Liposome-mediated augmentation of superoxide dismutase in endothelial cells prevents oxygen injury. J Biol Chem 1983; 258: 12534-42.
32. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007; 87: 315-424.
33. Sies H, Sharov VS, Klotz LO, Briviba K. Glutathione peroxidase protects against peroxynitrite-mediated oxidations. A new function for selenoproteins as peroxynitrite reductase. J Biol Chem 1997; 272: 27812-7.
34. Akaike T, Noguchi Y, Ijiri S, et al. Pathogenesis of influenza virus-induced pneumonia: Involvement of both nitric oxide and oxygen radicals. Proc Natl Acad Sci USA 1996; 93: 2448-53.
35. Titheradge MA. Nitric oxide in septic shock. Biochim Biophys Acta-Bioenergetics 1999; 1411: 437-55.
36. Di Filippo C, Verza M, Coppola L, Rossi F, D'Amico M, Marfella R. Insulin resistance and postprandial hyperglycemia the bad companions in natural history of diabetes: effects on health of vascular tree. Curr Diabetes Rev 2007; 3: 268-73.
37. Milstien S, Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. Biochem Biophys Res Commun 1999; 263: 681-4.
38. Cosentino F, Patton S, d'Uscio LV, et al. Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest 1998; 101: 1530-7.
39. Upmacis RK, Crabtree MJ, Deeb RS, et al. Profound biopterin oxidation and protein tyrosine nitration in tissues of ApoE-null mice on an atherogenic diet: contribution of inducible nitric oxide synthase. Am J Physiol Heart Circ Physiol 2007; 293(5): H2878-87.
40. Crabtree MJ, Smith CL, Lam G, Goligorsky MS, Gross SS. Ratio of 5,6,7,8-tetrahydrobiopterin to 7,8-dihydrobiopterin in endothelial cells determines glucose-elicited changes in NO vs. superoxide production by eNOS. Am J Physiol-Heart Circ Physiol 2008; 294: H1530-H40.
41. Pieper GM. Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin. J Cardiovasc Pharmacol 1997; 29: 8-15.
42. Verhaar MC, Westerweel PE, van Zonneveld AJ, Rabelink TJ. Free radical production by dysfunctional eNOS. Heart 2004; 90: 494-5.
43. Porkert M, Sher S, Reddy U, et al. Tetrahydrobiopterin: a novel antihypertensive therapy. J Hum Hypertens 2008; 22: 401-7.
44. Antoniades C, Shirodaria C, Crabtree M, et al. Altered plasma versus vascular biopterins in human atherosclerosis reveal relationships between endothelial nitric oxide synthase coupling, endothelial function, and inflammation. Circulation 2007; 116: 2851-9.
45. d'Uscio LV, Milstien S, Richardson D, Smith L, Katusic ZS. Long-term vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity. Circ Res 2003; 92: 88-95.
46. Huang A, Vita JA, Venema RC, Keaney JF. Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin. J Biol Chem 2000; 275: 17399-406.
47. Schock BC, Van der Vliet A, Corbacho AM, et al. Enhanced inflammatory responses in alpha-tocopherol transfer protein null mice. Arch Biochem Biophys 2004; 423: 162-9.
48. van Etten RW, de Koning EJ, Verhaar MC, Gaillard CA, Rabelink TJ. Impaired NO-dependent vasodilation in patients with Type II (non-insulin- dependent) diabetes mellitus is restored by acute administration of folate. Diabetologia 2002; 45: 1004-10.
49. Antoniades C, Shirodaria C, Warrick N, et al. 5- methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels - Effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 2006; 114: 1193-201.
50. Crabtree MJ, Tatham AL, Al-Wakeel Y, et al. Quantitative regulation of intracellular endothelial nitric oxide synthase (eNOS) coupling by both tetrahydrobiopterin-eNOS stoichiometry and biopterin redox status: Insights from cells with tet-regulated GTP cyclohydrolase I expression. J Biol Chem 2008; 284: 1136-44.
51. Johnson FK, Johnson RA, Peyton KJ, Durante W. Arginase inhibition restores arteriolar endothelial function in Dahl rats with salt-induced hypertension. Am J Physiol Regul Integr Comp Physiol 2005; 288: R1057-62.
52. Cooke JP, Singer aH, Tsao P, Zera P, Rowan Ra, Billingham ME. Antiatherogenic Effects of L-Arginine in the Hypercholesterolemic Rabbit. J Clin Invest 1992; 90: 1168-72.
53. Creager Ma, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. L-Arginine Improves Endothelium-Dependent Vasodilation in Hypercholesterolemic Humans. J Clin Invest 1992; 90: 1248-53.
54. Wennmalm A, Edlund A, Granstrom EF, Wiklund O. Acute supplementation with the nitric oxide precursor L-arginine does not improve cardiovascular performance in patients with hypercholesterolemia. Atherosclerosis 1995; 118: 223-31.
55. Oomen CM, van Erk MJ, Feskens EJ, Kok FJ, Kromhout D. Arginine intake and risk of coronary heart disease mortality in elderly men. Arterioscler Thromb Vasc Biol 2000; 20: 2134-9.
56. Ryoo S, Gupta G, Benjo A, et al. Endothelial arginase II: a novel target for the treatment of atherosclerosis. Circ Res 2008; 102: 923-32.
57. Moncada S. Biology and therapeutic potential of prostacyclin. Stroke 1983; 14: 157-68.
58. Moncada S. Prostacyclin and arterial wall biology. Arterioscler Thromb Vasc Biol 1982; 2: 193-207.
59. Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989; 86: 3375-8.
60. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; 2: 997-1000.
61. Mitchell JA, de Nucci G, Warner TD, Vane JR. Different patterns of release of endothelium-derived relaxing factor and prostacyclin. Br J Pharmacol 1992; 105: 485-9.
62. Dinchuk JE, Car BD, Focht RJ, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995; 378: 406-9.
63. Morham SG, Langenbach R, Loftin CD, et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995; 83: 473-82.
64. Yokoyama C, Yabuki T, Shimonishi M, et al. Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction. Circulation 2002; 106: 2397-403.
65. Murata T, Ushikubi F, Matsuoka T, et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997; 388: 678-82.
66. Eikelboom JW, Hankey GJ, Thom J, et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation 2008; 118: 1705-12.
67. Schildknecht S, Bachschmid M, Baumann A, Ullrich V. COX-2 inhibitors selectively block prostacyclin synthesis in endotoxin-exposed vascular smooth muscle cells. FASEB J 2004; 18: 757-9.
68. Kaye AD, Baluch A, Kaye AJ, Ralf G, Lubarsky D. Pharmacology of cyclooxygenase-2 inhibitors and preemptive analgesia in acute pain management. Curr Opin Anaesthesiol 2008; 21: 439-45.
69. Chenevard R, Hurlimann D, Bechir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003; 107: 405-9.
70. Widlansky ME, Price DT, Gokce N, et al. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension 2003; 42: 310-5.
71. O'Banion MK. Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Crit Rev Neurobiol 1999; 13: 45-82.
72. Hermann M, Camici G, Fratton A, et al. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation 2003; 108: 2308-11.
73. Abdelrahman AM, Al Suleimani YM. Four-week administration of nimesulide, a cyclooxygenase-2 inhibitor, improves endothelial dysfunction in the hindlimb vasculature of streptozotocin-induced diabetic rats. Arch Pharm Res 2008; 31: 1584-9.
74. Chegaev K, Lazzarato L, Tosco P, et al. NO-donor COX-2 inhibitors. new nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties. J Med Chem 2007; 50: 1449-57.
75. Bolla M, Momi S, Gresele P, Del Soldato P. Nitric oxide-donating aspirin (NCX 4016): an overview of its pharmacological properties and clinical perspectives. Eur J Clin Pharmacol 2006; 62: 145-54.
76. Mackenzie IS, Rutherford D, MacDonald TM. Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis. Arthritis Res Ther 2008; 10 Suppl 2: S3.
77. Cantoni O, Tommasini I, Cerioni L. The arachidonate-dependent survival signaling preventing toxicity in monocytes/macrophages exposed to peroxynitrite. Methods Enzymol 2008; 441: 73-82.
78. Nuriel T, Deeb RS, Hajjar DP, Gross SS. Protein 3-nitrotyrosine in complex biological samples: quantification by high-pressure liquid chromatography/electrochemical detection and emergence of proteomic approaches for unbiased identification of modification sites. Methods Enzymol 2008; 441: 1-17.
79. Nogawa S, Forster C, Zhang F, Nagayama M, Ross ME, Iadecola C. Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia. Proc Natl Acad Sci USA 1998; 95: 10966-71.
80. Baker CS, Hall RJ, Evans TJ, et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol 1999; 19: 646-55.
81. Deeb RS, Shen H, Gamss C, et al. Inducible nitric oxide synthase mediates prostaglandin H-2 synthase nitration and suppresses eicosanoid production. Am J Pathol 2006; 168: 349-62.
82. Marnett LJ, Wright TL, Crews BC, Tannenbaum SR, Morrow JD. Regulation of prostaglandin biosynthesis by nitric oxide is revealed by targeted deletion of inducible nitric-oxide synthase. J Biol Chem 2000; 275: 13427-30.
83. Kim SF, Huri DA, Snyder SH. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 2005; 310: 1966-70.
84. Gole MD, Souza JM, Choi I, et al. Plasma proteins modified by tyrosine nitration in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 2000; 278: L961-7.
85. Deeb RS, Hao G, Gross SS, et al. Heme catalyzes tyrosine 385 nitration and inactivation of prostaglandin H-2 synthase-1 by peroxynitrite. J Lipid Res 2006; 47: 898-911.
86. Hodara R, Norris EH, Giasson BI, et al. Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J Biol Chem 2004; 279: 47746-53.
87. Pietraforte D, Salzano AM, Scorza G, Marino G, Minnetti M. Mechanism of peroxynitrite interaction with ferric hemoglobin and identification of nitrated tyrosine residues. CO2 inhibits heme-catalyzed scavenging and isomerization. Biochemistry 2001; 40: 15300-9.
88. Schmidt P, Youhnovski N, Daiber A, et al. Specific nitration at tyrosine 430 revealed by high resolution mass spectrometry as basis for redox regulation of bovine prostacyclin synthase. J Biol Chem 2003; 278: 12813-9.
89. Daiber A, Bachschmid M, Beckman JS, Munzel T, Ullrich V. The impact of metal catalysis on protein tyrosine nitration by peroxynitrite. Biochem Biophys Res Commun 2004; 317: 873-81.
90. Lu H, Rateri DL, Feldman DL, Jr RJ, et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest 2008; 118: 984-93.
91. Boustany CM, Brown DR, Randall DC, Cassis LA. AT1-receptor antagonism reverses the blood pressure elevation associated with diet-induced obesity. Am J Physiol Regul Integr Comp Physiol 2005; 289: R181-6.
92. Prasad A, Quyyumi AA. Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation 2004; 110: 1507-12.
93. Hu C, Dandapat A, Chen J, et al. Over-expression of angiotensin II type 2 receptor (agtr2) reduces atherogenesis and modulates LOX-1, endothelial nitric oxide synthase and heme-oxygenase-1 expression. Atherosclerosis 2008; 199: 288-94.
94. Luscher TF, Tanner FC. Endothelial regulation of vascular tone and growth. Am J Hypertens 1993; 6: 283S-93S.
95. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996; 94: 2756-67.
96. Schramek H, Coroneos E, Dunn MJ. Interactions of the vasoconstrictor peptides, angiotensin II and endothelin-1, with vasodilatory prostaglandins. Semin Nephrol 1995; 15: 195-204.
97. Tummala PE, Chen XL, Sundell CL, et al. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis. Circulation 1999; 100: 1223-9.
98. Pastore L, Tessitore A, Martinotti S, et al. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 1999; 100: 1646-52.
99. Mombouli JV. ACE inhibition, endothelial function and coronary artery lesions. Role of kinins and nitric oxide. Drugs 1997; 54 (Suppl 5): 12-22.
100. Group PC. Blood-pressure lowering for the secondary prevention of stroke. Lancet 2001; 358: 1033-41.
101. Schluter KD, Wenzel S. Angiotensin II: A hormone involved in and contributing to pro-hypertrophic cardiac networks and target of anti-hypertrophic cross-talks. Pharmacol Ther 2008; 119: 311-25.
102. Searles CD, Harrison DG. The interaction of nitric oxide, bradykinin, and the angiotensin II type 2 receptor: lessons learned from transgenic mice. J Clin Invest 1999; 104: 1013-4.
103. Liu YH, Yang XP, Sharov VG, et al. Effects of angiotensin- converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997; 99: 1926-35.
104. Tsutsumi Y, Matsubara H, Masaki H, et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999; 104: 925-35.
105. Lu H, Rateri DL, Cassis LA, Daugherty A. The role of the renin-angiotensin system in aortic aneurysmal diseases. Curr Hypertens Rep 2008; 10: 99-106.
106. Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM, Husain A. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993; 91: 1269-81.
107. Petrie MC, Padmanabhan N, McDonald JE, Hillier C, Connell JM, McMurray JJ. Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol 2001; 37: 1056-61.
108. Bader M, Peters J, Baltatu O, Muller DN, Luft FC, Ganten D. Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research. J Mol Med 2001; 79: 76-102.
109. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II receptors in normal and failing human hearts. J Clin Endocrinol Metab 1989; 69: 54-66.
110. Cassis LA, English VL, Bharadwaj K, Boustany CM. Differential effects of local versus systemic angiotensin II in the regulation of leptin release from adipocytes. Endocrinology 2004; 145: 169-74.
111. Silver RB, Reid AC, Mackins CJ, et al. Mast cells: a unique source of renin. Proc Natl Acad Sci USA 2004; 101: 13607-12.
112. Nakata S, Tsutsui M, Shimokawa H, et al. Spontaneous myocardial infarction in mice lacking all nitric oxide synthase isoforms. Circulation 2008; 117: 2211-23.
113. Rush JW, Aultman CD. Vascular biology of angiotensin and the impact of physical activity. Appl Physiol Nutr Metab 2008; 33: 162-72.
114. Szentivanyi M, Jr., Zou AP, Mattson DL, Soares P, et al. Renal medullary nitric oxide deficit of Dahl S rats enhances hypertensive actions of angiotensin II. Am J Physiol Regul Integr Comp Physiol 2002; 283: R266-72.
115. Zhou MS, Adam AG, Jaimes EA, Raij L. In salt-sensitive hypertension, increased superoxide production is linked to functional upregulation of angiotensin II. Hypertension 2003; 42: 945-51.
116. Khan BV, Navalkar S, Khan QA, Rahman ST, Parthasarathy S. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease. J Am Coll Cardiol 2001; 38: 1662-7.
117. Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, Chayama K. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med 2002; 346: 1954-62.
118. Tojo A, Onozato ML, Kobayashi N, Goto A, Matsuoka H, Fujita T. Angiotensin II and oxidative stress in Dahl Salt-sensitive rat with heart failure. Hypertension 2002; 40: 834-9.
119. Kobori H, Nishiyama A, Abe Y, Navar LG. Enhancement of intrarenal angiotensinogen in Dahl salt-sensitive rats on high salt diet. Hypertension 2003; 41: 592-7.
120. Jaimes EA, Zhou MS, Pearse DD, Puzis L, Raij L. Upregulation of cortical COX-2 in salt-sensitive hypertension: role of angiotensin II and reactive oxygen species. Am J Physiol Renal Physiol 2008; 294: F385-92.
121. Moroi M, Zhang L, Yasuda T, et al. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J Clin Invest 1998; 101: 1225-32.
122. Cook S, Hugli O, Egli M, et al. Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. Swiss Med Wkly 2003; 133: 360-3.
123. Duplain H, Burcelin R, Sartori C, et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 2001; 104: 342-5.
124. Huang A, Sun D, Shesely EG, Levee EM, Koller A, Kaley G. Neuronal NOS-dependent dilation to flow in coronary arteries of male eNOS-KO mice. Am J Physiol Heart Circ Physiol 2002; 282: H429-36.
125. Lamping KG, Nuno DW, Shesely EG, Maeda N, Faraci FM. Vasodilator mechanisms in the coronary circulation of endothelial nitric oxide synthase-deficient mice. Am J Physiol Heart Circ Physiol 2000; 279: H1906-12.